Leap Therapeutics

Yahoo Finance • last year

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum... Full story

Yahoo Finance • 2 years ago

BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate

https://cdn.benzinga.com/files/images/story/2023/03/17/lptx.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Leap Therapeutics Inc (NASDAQ: LPTX) announced BeiGene Ltd's (NASDAQ: BGNE) option under the Exclusive Option, and License Agr... Full story

Yahoo Finance • 2 years ago

Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mer... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AQUA, LPTX, ALR

NEW YORK, Feb. 05, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of ATCX, CEMI, LPTX, and AQUA

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Atlas Technical Consultants, Inc. (NASDAQ: ATCX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ATCX to GI Partners for $... Full story

Yahoo Finance • 2 years ago

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, y... Full story

Yahoo Finance • 2 years ago

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas Medicine, Inc. EDIT is making good progress with the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes b... Full story

Yahoo Finance • 2 years ago

Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why

Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. Zacks Investment Research Image Source: Zacks Investment Research The company’s sole marketed drug, Nup... Full story

Yahoo Finance • 3 years ago

Shareholders in Leap Therapeutics (NASDAQ:LPTX) are in the red if they invested five years ago

Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held Leap Therapeutics, Inc. (NASDAQ:LPTX) for five whole years - as the... Full story